<DOC>
	<DOC>NCT00464789</DOC>
	<brief_summary>Bazedoxifene/Conjugated Estrogens (BZA/CE) is an investigational drug that is being developed for treatment of menopause. The purpose of this trial is to compare a new manufacturing process for making BZA/CE to the current process by assessing the way it is absorbed into the blood.</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal women aged 35 to 70 years Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg Healthy as determined by the investigator on the basis of medical history, physical examination, breast and gynecologic examination, clinical laboratory test results, vital signs, and 12lead electrocardiogram (ECG). Any clinically important active condition of gynecologic, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies. History of any clinically important drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs).</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Postmenopausal</keyword>
</DOC>